Skip to content

Clinical Study on the Effect of Probiotic Compound Powder on the Immunity Improvement of Preschool Children

A Clinical Study on The Effect of Probiotic Compound Powder (WONDERLAB) on The Immunity Improvement of Preschool Children (RCT)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05585021
Enrollment
140
Registered
2022-10-18
Start date
2022-10-19
Completion date
2023-04-30
Last updated
2023-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunity

Keywords

Rotavirus, Upper respiratory tract infection, Bristol scoring method

Brief summary

This is a randomized controlled trial, to evaluate the effect of WONDERLAB Probiotic Compound Powder on improving immunity of preschool children

Detailed description

The community hospital will recruit 140 preschool children, aged 5 to 6 years old, according to the inclusion and exclusion criteria, and randomly assigned them to 2 groups. 70 subjects in the placebo group and 70 in the experimental product group. First entered a one-week washout period, and then entered a 25-week clinical intervention, and finally ensured that 100 volunteers completed the whole study, and the withdrawal rate was about 28%.

Interventions

DIETARY_SUPPLEMENTWonderlab Kids instant probiotics

During study intervention, subjects are required to take the randomly assigned product based on the randomization list. Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, take it half an hour after meal.1 bottle a day. Lasting for 24 weeks intervention period.

DIETARY_SUPPLEMENTInstant probiotic placebo

Subjects are required to take the randomly assigned Instant probiotic placebo based on the randomization list. Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, half an hour after meal. 1 bottle a day. Lasting for 24 weeks intervention period.

Sponsors

Shenzhen Precision Health Food Technology Co. Ltd.,
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Investigator)

Intervention model description

The community hospital will recruit 140 preschool children, aged 5 to 6 years old, according to the inclusion and exclusion criteria, and randomly assigned them to 2 groups. 70 subjects in the placebo group and 70 in the experimental product group. First entered a one-week washout period, and then entered a 25-week clinical intervention, and finally ensured that 100 volunteers completed the whole study, and the withdrawal rate was about 28%.

Eligibility

Sex/Gender
ALL
Age
5 Years to 6 Years
Healthy volunteers
No

Inclusion criteria

* Preschool children, male or female, 5 to 6 years old; * Those with weak constitution and easy to get sick: One of them can be satisfied: AGet cold ≥ 3 times a year B Bronchitis or pneumonia ≥2 times per year C Rotavirus diarrhea ≥1 time per year * During the trial, participants agree not to take any drugs, supplements, or other dairy products containing probiotics; * During the trial, participants agree not to take any other prebiotic/bacterial drugs, supplements, or dairy products including yogurt drinks; * Willing to refrain from participating in other interventional clinical studies during the trial period; * Be able to fully understand the nature, purpose, benefits and possible risks and side effects of the research; * Willing to obey all test requirements and procedures; * Informed consent signed by parents or legal guardians.

Exclusion criteria

* Subject who is in the treatment of gastrointestinal diseases; * Subject who has lactose intolerance; * The subjects are currently suffering from other organic diseases that affect intestinal function, such as history of gastrointestinal resection, colonic or rectal cancer, inflammatory bowel disease, diabetes, hyperthyroidism or hypothyroidism, Hirschsprung's disease, scleroderma, anorexia nervosa, etc.; * Subjects have any of the following medical histories or clinically diagnosed diseases that may affect the evaluation of the test effect: obvious gastrointestinal dysfunction, liver, kidney, endocrine, blood, respiratory and cardiovascular diseases; * According to the judgment of the researchers, frequent use of drugs that may affect gastrointestinal function or the immune system; * Subjects who took laxatives or other digestive aids 2 weeks before the start of the study; * Consumed dairy products or other foods containing prebiotics/bacteria within 10 days before the start of the study; * PI believes that volunteers cannot fully cooperate with the trial arrangement.

Design outcomes

Primary

MeasureTime frameDescription
Infection of the upper respiratory tract at endpointendpoint ( day 168)Drug records of upper respiratory tract infection within past 168 days.
Rotavirus diarrhea Testing at baselinebaseline(day 0)Records of sick leave days, medical visits and hospitalization days due to rotavirus infection within past 12 month
Rotavirus diarrhea Testing at endpointendpoint( day 168)Records of sick leave days, medical visits and hospitalization days due to rotavirus infection within past 168 days
Infection of the upper respiratory tract at baselinebaseline(day 0)Drug records of upper respiratory tract infection within past 12 months.

Secondary

MeasureTime frameDescription
Bristol Stool Chartbaseline(day 0)/interim ( day 84)/endpoint( day 168)/recession period( day 175)To evaluate samples of human feces based on the shape and consistency of the stool.
Faecesbaseline(day 0)/interim ( day 84)/endpoint( day 168)/recession period( day 175)sIgA 、16sRNA、SCFA、Fecal calprotectin
Salivabaseline(day 0)/interim ( day 84)/endpoint( day 168)/recession period( day 175)sIgA testing
Pittsburgh sleep quality indexbaseline(day 0)/interim ( day 84)/endpoint( day 168)18 items comprise 7 components, each of which is scored according to o\ 3 grade. The cumulative score of each component is the total score of PSQI, with a total score range of 0\ 2l. The higher the score, the worse the sleep quality.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026